For journalists, podcasters, and newsletter writers
Designing Longevity is an independent editorial operation that publishes verifiable, primary-source-linked analysis of telehealth providers in GLP-1, hormone replacement, and DTC lab testing. If you are covering a story in this space, the following resources may be useful.
What we have that may be useful
2025-2026 Telehealth Provider Regulatory Timeline
Comprehensive chronological reference covering 15+ events: the September 2025 and March 2026 FDA enforcement waves on compounded GLP-1 (with primary-source warning-letter URLs), Eli Lilly v. multiple compounders (with court docket links), the Novo Nordisk-Hims dispute and settlement, the Washington State Notice of Immediate Jeopardy on Aequita Pharmacy (Mochi Health-affiliated), the February 2025 FDA class-wide testosterone labeling changes, and more. Every event has at least one primary-source URL, HEAD-checked at publish time.
View the timelineVetted provider directory (13 providers)
Independently scored on a public six-dimension rubric: licensure, accreditation, transparency, product quality, pricing, customer service. Every score has a one-line rationale and source URLs for the verifications behind it. Cohort spans GLP-1 (compounded and brand-name), hormone-TRT, and DTC lab testing. The directory specifically surfaces negatives that affiliate-driven competitors typically hide (BBB F ratings, Trustpilot suspected-fraudulent-review notices, active manufacturer lawsuits).
Browse the directoryHead-to-head comparisons (20 pairs)
Per-criterion verdicts with reasoning across every possible within-category pair: compounded GLP-1, branded GLP-1, hormone-TRT, and DTC lab testing. Useful when reporting on consumer-decision angles or comparing operational practices across providers.
Browse comparisonsEditorial methodology and rubric
Six-dimension scoring rubric with public weights. Tier-based verification process. Hard lines on compensation (per-click and per-qualified-consult only, never per-prescription, never pay-to-rank). Useful if you need to characterize how the directory works.
Read the methodology
Story angles we have unusual data on
Areas where our coverage goes deeper than typical affiliate-review sites and where we may be a useful primary or secondary source:
Aequita Pharmacy / Mochi Health enforcement
The Washington State Department of Health Pharmacy Quality Assurance Commission issued a Limited Stop Service against Aequita that escalated to a Notice of Immediate Jeopardy after substantiated whistleblower allegations of unlicensed-worker sterile compounding and improper cold-chain shipping (Otter Pops in lieu of medical-grade ice packs, per KING 5 News). We have the WA State and KING 5 source links indexed alongside the Mochi profile, including documentation that Aequita's listed owner signed an Agreed Order in July 2025 that did not contest the findings.
Eli Lilly v. multiple compounders (4:25-cv-03536)
April 2025 N.D. Cal. lawsuits against Henry Meds (Adonis Health), Mochi Health, Fella Health, and Willow Health over compounded-tirzepatide marketing. We track the September 2025 partial-dismissal ruling on the Henry Meds motion (Judge Tigar; personalization claim survived) and link the Justia docket directly. Useful if you need a primary-source-linked timeline of where each defendant stands.
Novo Nordisk v. Mochi Health (5:25-cv-06563)
August 4, 2025 lawsuit filing as part of Novo's broader 14-defendant compounded-semaglutide enforcement. Notable for the unlicensed-corporate-practice-of-medicine claim under California law, which is structurally broader than typical Lanham Act marketing-only litigation. Justia docket linked from our regulatory timeline.
Hims-Novo Nordisk dispute timeline (2025-2026)
The full chronology from April 2025 partnership announcement through June 2025 termination, twin September 9, 2025 FDA warning letters (CMS #716567 and #716825), February 2026 lawsuit, and March 9, 2026 settlement that re-established Hims as an authorized branded GLP-1 seller. Each event is linked to its primary source.
Trustpilot suspected-fraudulent-review notice methodology
Trustpilot occasionally flags business profiles with a suspected-fraudulent-review notice. We weight that flag more heavily than headline star averages. Henry Meds carries the notice on its profile despite a 4.5/5 average across 12,300+ reviews; we've documented this in the Henry Meds profile and across multiple comparison pages. Useful framing for stories about review-platform manipulation.
How to reach us
Designing Longevity is a one-person editorial operation. The fastest way to reach the editor is email at support@infinitegrowventures.com. Please include your publication, the story angle, and your deadline if applicable. Same-day response on most inquiries.
A note on attribution
When citing the regulatory timeline or any individual provider profile, please link back to the specific page rather than the homepage. Each event in the timeline has its own primary-source URL; please cite those sources directly when possible. If you're writing about a specific finding (e.g., the Aequita enforcement) we'd appreciate being credited as the source where you encountered the documented chronology, especially if it shapes your reporting.